Mostrar el registro sencillo del ítem

dc.contributor.authorCaro, Carlos
dc.contributor.authorGámez, Francisco
dc.contributor.authorQuaresma, Pedro
dc.contributor.authorPáez-Muñoz, Jose María
dc.contributor.authorDomínguez, Alejandro
dc.contributor.authorPearson, John R.
dc.contributor.authorPernía Leal, Manuel
dc.contributor.authorBeltrán, Ana M.
dc.contributor.authorFernandez-Afonso, Yilian
dc.contributor.authorDe la Fuente, Jesús M.
dc.contributor.authorFranco, Ricardo
dc.contributor.authorPereira, Eulália
dc.contributor.authorGarcía-Martín, Maria Luisa
dc.date.accessioned2024-02-19T15:26:37Z
dc.date.available2024-02-19T15:26:37Z
dc.date.issued2021-03-20
dc.identifier.otherhttp://hdl.handle.net/10668/4488
dc.identifier.urihttp://hdl.handle.net/20.500.12105/18292
dc.description.abstractIn this study, we report the synthesis of gold-coated iron oxide nanoparticles capped with polyvinylpyrrolidone (Fe@Au NPs). The as-synthesized nanoparticles (NPs) exhibited good stability in aqueous media and excellent features as contrast agents (CA) for both magnetic resonance imaging (MRI) and X-ray computed tomography (CT). Additionally, due to the presence of the local surface plasmon resonances of gold, the NPs showed exploitable "light-to-heat" conversion ability in the near-infrared (NIR) region, a key attribute for effective photothermal therapies (PTT). In vitro experiments revealed biocompatibility as well as excellent efficiency in killing glioblastoma cells via PTT. The in vivo nontoxicity of the NPs was demonstrated using zebrafish embryos as an intermediate step between cells and rodent models. To warrant that an effective therapeutic dose was achieved inside the tumor, both intratumoral and intravenous routes were screened in rodent models by MRI and CT. The pharmacokinetics and biodistribution confirmed the multimodal imaging CA capabilities of the Fe@AuNPs and revealed constraints of the intravenous route for tumor targeting, dictating intratumoral administration for therapeutic applications. Finally, Fe@Au NPs were successfully used for an in vivo proof of concept of imaging-guided focused PTT against glioblastoma multiforme in a mouse model.
dc.description.sponsorshipFinancial support was provided by the Spanish Ministry of Economy, Industry and Competitiveness (CTQ2017-86655-R and BIO2017-84246-C2-1-R), Fondo Social de la DGA (grupos DGA) and by the Regional Ministry of Health of Andalusia (OH-0026-2018). This work was supported by the Associate Laboratory for Green Chemistry—LAQV, and by the Applied Molecular Biosciences Unit –UCIBIO, both financed by Portuguese national funds from FCT/MCTES (UIDB/04378/2020 and UIDB/50006/2020).
dc.language.isoeng
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) 
dc.type.hasVersionVoR
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectImaging-guided therapy
dc.subjectMultimodal imaging
dc.subjectContrast agent
dc.subjectMRI
dc.subjectCT
dc.subjectPhotothermal therapy
dc.subjectZebrafish
dc.subjectTemperature
dc.subjectTissues
dc.subjectNanoparticles
dc.subjectImagen multimodal
dc.subjectMedios de contraste
dc.subjectImagen por resonancia magnética
dc.subjectTomografíacComputarizada por rayos X
dc.subjectTerapia fototérmica
dc.subjectPez cebra
dc.subjectTemperatura
dc.subjectTejidos
dc.subjectNanopartículas
dc.subjectNeoplasias
dc.subject.meshAnimals 
dc.subject.meshMice 
dc.subject.meshContrast Media 
dc.subject.meshZebrafish 
dc.subject.meshSurface Plasmon Resonance 
dc.subject.meshPovidone 
dc.subject.meshHot Temperature 
dc.subject.meshRodentia 
dc.subject.meshTissue Distribution 
dc.subject.meshMetal Nanoparticles 
dc.subject.meshMultimodal Imaging 
dc.subject.meshTomography, X-Ray Computed 
dc.subject.meshMagnetic Resonance Imaging 
dc.subject.meshNeoplasms 
dc.titleFe3O4-Au Core-Shell Nanoparticles as a Multimodal Platform for In Vivo Imaging and Focused Photothermal Therapy
dc.typeresearch article
dc.rights.licenseAttribution 4.0 International*
dc.identifier.pubmedID33804636es_ES
dc.identifier.doi10.3390/pharmaceutics13030416
dc.identifier.e-issn1999-4923es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/13/3/416es
dc.identifier.journalPharmaceuticses_ES
dc.rights.accessRightsopen accesses_ES
dc.contributor.authoraffiliation[Caro,C; Páez-Muñoz,JM; Domínguez,A; Pearson,JR; García-Martín,ML] BIONAND—Centro Andaluz de Nanomedicina y Biotecnología (Junta de Andalucía-Universidad de Málaga), Málaga, Spain. [Gámez,F] Departamento de Química Física, Universidad de Granada, Granada, Spain. [Quaresma,P: Pereira,E] REQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Porto, Portugal. [Pernía Leal,M] Departamento de Química Orgánica y Farmacéutica, Facultad de Farmacia, Universidad de Sevilla, Seville, Spain. [Beltrán,AM] Departamento de Ingeniería y Ciencia de los Materiales y del Transporte, Escuela Politécnica Superior, Universidad de Sevilla, Sevilla, Spain. [Fernandez-Afonso,Y; De la Fuente,JM] Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza, Spain. [De la Fuente,JM; García-Martín,ML] Biomedical Research Networking Center in Bioengineering, Biomaterials &Nanomedicine (CIBER-BBN), Madrid, Spain [Franco,R] UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, Portugal.


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution 4.0 International
Este Item está sujeto a una licencia Creative Commons: Attribution 4.0 International